<DOC>
	<DOCNO>NCT00904462</DOCNO>
	<brief_summary>Patients unilateral bilateral osteoarthritis ( OA ) knee participate Phase II clinical trial ass efficacy lidocaine 5 % patch compare placebo treatment pain OA knee .</brief_summary>
	<brief_title>Pilot Study Lidocaine 5 % Patch Versus Placebo Patients With Osteoarthritis Pain Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Key 1 . Had unilateral bilateral OA knee diagnose accord American College Rheumatology ( ACR ) criterion base clinical radiographic evidence ( presence osteophytes xray write evaluation ) OA 2 . Had functional capacity class rating I , II , III accord ACR classification 3 . Had normal 12lead electrocardiogram ( ECG ) without clinically significant abnormality heart rate , rhythm , conduction 4 . Had discontinue use analgesic medication ( include overthecounter [ OTC ] analgesic ) prior randomization ( patient allow limited use analgesic medication non study pain 5 . At baseline visit , patient randomize doubleblind treatment average pain intensity rating index joint 6 great ( 0 10 scale ) least 3 day 5 consecutive day immediately prior baseline visit ; 0 define `` pain '' 10 define `` pain bad ever imagine '' measure Question 5 BPI record diary 6 . At baseline visit , patient randomize doubleblind treatment , baseline visit , OA severity score index joint 7 great composite scale 0 24 measure Index Severity Osteoarthrosis Knee Key 1 . Had diagnose inflammatory arthritis , gout , pseudogout Paget 's disease investigator 's opinion would interfere assessment pain symptom OA 2 . Had serious medical condition require daily medication , anticonvulsant tricyclic antidepressant , could confound study result 3 . Had clinically significant joint disease prior joint replacement surgery index joint 4 . Had severe renal insufficiency ( creatinine clearance &lt; 30 mL/min ) 5 . Had moderate great hepatic impairment 6 . Were take analgesic medication , glucosamine , chondroitin could discontinue study . Patients take medication prior study require discontinue use duration study . Patients use opioid analgesic study entry require taper medication . 7 . Were take longacting opioids opioids could discontinue first 5 day placebo runin period . 8 . Were use lidocainecontaining product could discontinue study 9 . Had previously fail treatment Lidoderm analgesic patch OA 10 . Had recently receive either corticosteroid injection ( within 8 week ) hyaluronic acid ( within 6 month ) study entry 11 . Were unable discontinue use topical drug apply knee 12 . Were take class I antiarrhythmic drug ( e.g . mexiletine , tocainide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>